Clinical research
Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
The Centers for Medicare and Medicaid Services indicated it would cover the cost of these drugs and any necessary scans — but only “if they are enrolled in qualifying clinical trials.”
Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.
2021 could very well have been “the year of the vaccine.” While this modality is certainly not new, the COVID-19 pandemic is sparking excitement about just what else they might be able to do.
Amicus announced that it is halting its CLN6 Batten disease gene therapy program after studies failed to achieve consistent results.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start Monday with deal announcements and plans to drive biopharma companies through the coming year.
Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.
Another drug Vounatsos heralded was zuranolone, which Biogen is developing with Sage Therapeutics for multiple forms of depression.
PRESS RELEASES